Summarized by Masters of Longevity from Fight Aging!.
A review examines mTOR biology and argues that inhibiting mTOR is context dependent across tissues and interventions, challenging one-size-fits-all pharmaceutical approaches.
Key Takeaways
- Countless animal studies have been conducted, and early clinical trials for novel mTOR inhibitors have taken place.
- The mTOR inhibitor rapamycin is a generic, low cost drug now used by a growing number of people for its potential to slow aging.
- Today's open access review is a short deep dive into the biochemistry of mTOR, the role of mTOR in aging, and ability of mTOR inhibitors to modestly slow aging.
